Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 1980-1984  (4)
  • thromboxane synthetase inhibitors  (2)
  • erythromycin  (1)
  • flecainide  (1)
  • 1
    Electronic Resource
    Electronic Resource
    The effect of a new antiarrhythmic agent, flecainide acetate, on systolic time intervals (1983)
    Springer
    European journal of clinical pharmacology 25 (1983), S. 13-18 
    Details
    ISSN: 1432-1041
    Keywords: flecainide ; antiarrhythmic agent ; systolic time intervals ; heart functions ; conduction delay ; myocardial contractility
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary We investigated the effect of flecainide on systolic time intervals in 6 healthy subjects. A randomized, double blind, cross-over study was designed using flecainide (2 mg/kg), propranolol (0.2 mg/kg) or saline. In comparison with placebo, flecainide increased heart rate, diastolic BP, QT-Index, QS2-Index, PEP, and reduced LVET-Index (p〈0.05). It caused a significant increase in PR interval, QRS duration, and PEP/LVET (p〈0.01). Propranolol, compared with placebo, decreased heart rate and systolic BP (p〈0.05). It increased PR interval, PEP, and PEP/LVET ratio (p〈0.05). In comparison with propranolol, flecainide increased heart rate and QRS duration (p〈0.01, p〈0.001 respectively). It increased diastolic BP, PR interval, QS2-Index, PEP, and PEP/LVET ratio, and decreased LVET-Index (p〈0.05). These changes in STI induced by flecainide may be produced by depression of myocardial contractility. Intraventricular conduction delay may be an additional contributing factor.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00544007
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome (1984)
    Springer
    European journal of clinical pharmacology 27 (1984), S. 61-65 
    Details
    ISSN: 1432-1041
    Keywords: thromboxane synthetase inhibitors ; Raynaud's syndrome ; systemic sclerosis ; UK-38,485 ; ischaemic attacks ; red blood cell rheology
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Ten patients with moderate to severe Raynaud's syndrome were recruited into a four week randomised double blind crossover study to compare the efficacy of UK-38,485 50 mg, a new thromboxane synthetase inhibitor with that of placebo. With the doses used there was no significant difference between the two treatment periods in the number, severity and duration of ischaemic attacks, the mean hand temperatures, forearm and digital blood flow and red blood cell rheology.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00553156
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud’s syndrome (1984)
    Springer
    European journal of clinical pharmacology 27 (1984), S. 61-65 
    Details
    ISSN: 1432-1041
    Keywords: thromboxane synthetase inhibitors ; Raynaud’s syndrome ; systemic sclerosis ; UK-38,485 ; ischaemic attacks ; red blood cell rheology
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Ten patients with moderate to severe Raynaud’s syndrome were recruited into a four week randomised double blind crossover study to compare the efficacy of UK-38,485 50 mg, a new thromboxane synthetase inhibitor with that of placebo. With the doses used there was no significant difference between the two treatment periods in the number, severity and duration of ischaemic attacks, the mean hand temperatures, forearm and digital blood flow and red blood cell rheology.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02395208
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Should erythromycin dose be altered in haemodialysis patients? (1982)
    Springer
    European journal of clinical pharmacology 23 (1982), S. 435-440 
    Details
    ISSN: 1432-1041
    Keywords: erythromycin ; haemodialysis ; dosage adjustment ; pharmacokinetics ; protein-binding
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Erythromycin kinetics were studied in 17 patients with end stage renal failure treated with maintenance haemodialysis and 9 normal volunteers to discover if dialysis patients needed a modified dose. The elimination half life in dialysis patients (on dialysis days) was similar to that reported in normal subjects. Only small amounts of drug appeared in the dialysate, no patient loosing more than 9 mg in one dialysis. Both patients and volunteers had similar plasma concentrations 8 h after the end of a 5-day course. Protein-binding did not change significantly during dialysis and was similar to that reported in normal subjects. We conclude that dialysis patients requiring 1.5 g of erythromycin stearate daily or less can be given normal doses.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00605994
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...